TY - JOUR
KW - Adult
KW - Alcohol Deterrents/administration & dosage/adverse effects
KW - Alcoholism/drug therapy/psychology
KW - Behavior Therapy/methods
KW - Community Mental Health Centers
KW - Delayed-Action Preparations/administration & dosage
KW - Female
KW - Harm Reduction
KW - Homeless Persons/psychology
KW - Humans
KW - Injections, Intramuscular
KW - Male
KW - Middle Aged
KW - Naltrexone/administration & dosage/adverse effects
KW - Quality of Life
AU - S. E. Collins
AU - M. H. Duncan
AU - A. J. Saxon
AU - E. M. Taylor
AU - N. Mayberry
AU - J. O. Merrill
AU - G. E. Hoffmann
AU - S. L. Clifasefi
AU - R. K. Ries
A1 - 
AD - Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle, WA, USA; Department of Psychology, Washington State University, Spokane, WA, USA. Electronic address: susan.collins@wsu.edu.; Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle, WA, USA.; Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle, WA, USA; Center for Excellence in Substance Addiction Treatment and Education, VA Puget Sound Health Care System, Seattle, WA, USA.; Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle, WA, USA.; Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle, WA, USA.; Department of Medicine, Division of Internal Medicine, University of Washington School of Medicine, Seattle, WA, USA.; Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle, WA, USA.; Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle, WA, USA.; Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle, WA, USA.
BT - The Lancet.Psychiatry
C5 - Healthcare Disparities; Measures; Opioids & Substance Use
CP - 4
CY - England
DO - 10.1016/S2215-0366(20)30489-2
IS - 4
JF - The Lancet.Psychiatry
LA - eng
M1 - Journal Article
PB - Elsevier Ltd
PP - England
PY - 2021
SN - 2215-0374; 2215-0366
SP - 287
EP - 300
EP - 
T1 - Combining behavioral harm-reduction treatment and extended-release naltrexone for people experiencing homelessness and alcohol use disorder in the USA: a randomised clinical trial
T2 - The Lancet.Psychiatry
TI - Combining behavioral harm-reduction treatment and extended-release naltrexone for people experiencing homelessness and alcohol use disorder in the USA: a randomised clinical trial
U1 - Healthcare Disparities; Measures; Opioids & Substance Use
U2 - 33713622
U3 - 10.1016/S2215-0366(20)30489-2
VL - 8
VO - 2215-0374; 2215-0366
Y1 - 2021
Y2 - Apr
ER -